A genome‐scale network model and gene expression‐based score have been established to predict how metabolic perturbations affect sensitivity to HDAC inhibitors, and the sensitivity of multiple myeloma cells to DNMT inhibitors, respectively.114, 115. This evidence concerns the gene HDAC9 and plasma cell myeloma.